TRVN - トレベナ (Trevena Inc.)

TRVNのニュース

   Trevena Q2 2022 Earnings Preview (NASDAQ:TRVN)  2022/08/10 17:41:42 Seeking Alpha
Trevena (TRVN) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open.The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue…
   Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022  2022/08/08 11:00:00 GlobeNewswire
Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET
   Trevena Inc. (TRVN) can beat the pack with these strategies  2022/08/02 14:16:00 US Post News
Trevena Inc. (NASDAQ:TRVN) marked $0.22 per share on Monday, down from a previous closing price of $0.25. While Trevena Inc. has underperformed by -10.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TRVN fell by -83.37%, with highs and lows ranging from $1.54 to $0.18, whereas […]
   Should This Make Trevena Inc. (NASDAQ: TRVN) Investors Worry?  2022/08/01 13:30:00 Stocks Register
The trading price of Trevena Inc. (NASDAQ:TRVN) closed lower on Friday, July 29, closing at $0.25, -5.67% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.2366 and $0.254. In examining the 52-week price action we see that the stock hit a 52-week high … Should This Make Trevena Inc. (NASDAQ: TRVN) Investors Worry? Read More »
   Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock  2022/07/29 21:27:00 GlobeNewswire
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock (“Series A Preferred”) and 200 shares of Series B convertible preferred stock (“Series B Preferred”) and warrants exercisable to purchase up to an aggregate of 8,000,000 shares of common stock. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock. The warrants have an exercise price of $0.263 per share, will be exercisable beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the Company’s common stock in an amount sufficient to permit the exercise in full of the warrants, subject to stockholder approval of the reverse stock split, and will expire five and one-half years following the date of issuance.
   Is Trevena Inc. (NASDAQ: TRVN) Hit More of the Losses Given A -494.59% Dip From High?  2022/06/03 15:00:00 Marketing Sentinel
During the last session, Trevena Inc. (NASDAQ:TRVN)’s traded shares were 3.64 million, with the beta value of the company hitting 2.47. At the end of the trading day, the stock’s price was $0.37, reflecting an intraday gain of 10.94% or $0.04. The 52-week high for the TRVN share is $2.20, that puts it down -494.59 … Is Trevena Inc. (NASDAQ: TRVN) Hit More of the Losses Given A -494.59% Dip From High? Read More »
   Trevena Inc. (NASDAQ:TRVN) 16.84% Up Over The Last Seven Days. Can The Stock Hit Well Above $0.0354?  2022/05/20 13:00:00 Marketing Sentinel
In last trading session, Trevena Inc. (NASDAQ:TRVN) saw 1.28 million shares changing hands with its beta currently measuring 2.51. Company’s recent per share price level of $0.25 trading at -$0.02 or -9.97% at ring of the bell on the day assigns it a market valuation of $42.10M. That closing price of TRVN’s stock is at … Trevena Inc. (NASDAQ:TRVN) 16.84% Up Over The Last Seven Days. Can The Stock Hit Well Above $0.0354? Read More »
   Trevena Inc. (NASDAQ: TRVN) Is On The Rise  2022/05/17 13:00:00 Stocks Register
Trevena Inc. (NASDAQ:TRVN) traded at $0.30 at close of the session on Monday, 05/16/22, made an upward move of 49.16% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 2.27 with the day’s price range being $0.2056 – $0.36. In terms … Trevena Inc. (NASDAQ: TRVN) Is On The Rise Read More »
   Bears Are Back On The Defensive As Trevena Inc. (TRVN) tumbled -3.43%  2022/05/16 14:00:00 Marketing Sentinel
Trevena Inc. (NASDAQ:TRVN) has a beta value of 2.51 and has seen 1.66 million shares traded in the last trading session. The company, currently valued at $34.80M, closed the last trade at $0.20 per share which meant it lost -$0.01 on the day or -3.43% during that session. The TRVN stock price is -1000.0% off … Bears Are Back On The Defensive As Trevena Inc. (TRVN) tumbled -3.43% Read More »
   Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2022 Results - Earnings Call Transcript  2022/05/13 19:19:07 Seeking Alpha
Trevena, Inc. (NASDAQ:NASDAQ:TRVN) Q1 2022 Earnings Conference Call May 11, 2022 08:00 AM ET Company Participants Barry Shin - Senior Vice President & Chief Financial Officer Carrie…
   As The Stock Falls By -38.20% Year-To-Date, Trevena Inc. (NASDAQ: TRVN)’S Stock Continues To Progress In 2022  2022/04/23 19:00:00 Marketing Sentinel
During the last session, Trevena Inc. (NASDAQ:TRVN)’s traded shares were 0.7 million, with the beta value of the company hitting 2.32. At the end of the trading day, the stock’s price was $0.36, reflecting an intraday loss of -4.28% or -$0.02. The 52-week high for the TRVN share is $2.20, that puts it down -511.11 … As The Stock Falls By -38.20% Year-To-Date, Trevena Inc. (NASDAQ: TRVN)’S Stock Continues To Progress In 2022 Read More »
   Trevena reports data on effect of opioid drug Olinvyk in respiratory function in elderly  2022/04/20 12:05:26 Seeking Alpha
Trevena (TRVN) reported data from a study evaluating opioid drug Olinvyk (oliceridine) injection versus morphine for managing acute pain in elderly/overweight.The company said the…
   Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK and IV Morphine in Elderly/Overweight Subjects  2022/04/20 11:00:00 Wallstreet:Online
OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Data replicate observations previously seen in a comparative study of respiratory physiology in younger subjects with OLINVYK and IV morphine CHESTERBROOK, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company
   Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund  2022/04/18 11:00:00 Wallstreet:Online
CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge
   OLINVYK data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting  2022/04/13 20:05:00 Wallstreet:Online
CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recent medical meetings, relating to OLINVYK (oliceridine) injection, in several core therapeutic areas. Trevena attended

calendar